These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1995097)

  • 1. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors.
    Cummins LM; Weinhold KJ; Matthews TJ; Langlois AJ; Perno CF; Condie RM; Allain JP
    Blood; 1991 Mar; 77(5):1111-7. PubMed ID: 1995097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two different preparations of HIV immune globulin for efficiency of neutralization of HIV type 1 primary isolates.
    Nichols CN; Bernal I; Prince AM; Andrus L
    AIDS Res Hum Retroviruses; 2002 Jan; 18(1):49-56. PubMed ID: 11804556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of HIV infection by passive immunization with HIV immunoglobulin.
    Prince AM; Reesink H; Pascual D; Horowitz B; Hewlett I; Murthy KK; Cobb KE; Eichberg JW
    AIDS Res Hum Retroviruses; 1991 Dec; 7(12):971-3. PubMed ID: 1812946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.
    Prince AM; Horowitz B; Baker L; Shulman RW; Ralph H; Valinsky J; Cundell A; Brotman B; Boehle W; Rey F
    Proc Natl Acad Sci U S A; 1988 Sep; 85(18):6944-8. PubMed ID: 3413127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273).
    Stiehm ER; Fletcher CV; Mofenson LM; Palumbo PE; Kang M; Fenton T; Sapan CV; Meyer WA; Shearer WT; Hawkins E; Fowler MG; Bouquin P; Purdue L; Sloand EM; Nemo GJ; Wara D; Bryson YJ; Starr SE; Petru A; Burchett S
    J Infect Dis; 2000 Feb; 181(2):548-54. PubMed ID: 10669338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
    Mascola JR; Louder MK; VanCott TC; Sapan CV; Lambert JS; Muenz LR; Bunow B; Birx DL; Robb ML
    J Virol; 1997 Oct; 71(10):7198-206. PubMed ID: 9311792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS.
    Fletcher CV; Goodroad BK; Cummins LM; Henry K; Balfour HH; Rhame FS
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1571-4. PubMed ID: 9210687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera.
    Koup RA; Sullivan JL; Levine PH; Brewster F; Mahr A; Mazzara G; McKenzie S; Panicali D
    J Virol; 1989 Feb; 63(2):584-90. PubMed ID: 2536094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 neutralizing antibodies in urine from seropositive individuals.
    Cao YZ; Friedman-Kien AE; Mirabile M; Li XL; Alam M; Dieterich D; Ho DD
    J Acquir Immune Defic Syndr (1988); 1990; 3(3):195-9. PubMed ID: 1968094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.
    Nara PL; Robey WG; Arthur LO; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC; Fischinger PJ
    J Virol; 1987 Oct; 61(10):3173-80. PubMed ID: 2442411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins.
    Li A; Baba TW; Sodroski J; Zolla-Pazner S; Gorny MK; Robinson J; Posner MR; Katinger H; Barbas CF; Burton DR; Chou TC; Ruprecht RM
    AIDS Res Hum Retroviruses; 1997 May; 13(8):647-56. PubMed ID: 9168233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low number of functionally active B lymphocytes in the peripheral blood of HIV-1-seropositive individuals with low p24-specific serum antibody titers.
    Teeuwsen VJ; Lange JM; Keet R; Schattenkerk JK; Debouck C; van den Akker R; Goudsmit J; Osterhaus AD
    AIDS; 1991 Aug; 5(8):971-9. PubMed ID: 1723280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees.
    Gibbs CJ; Peters R; Gravell M; Johnson BK; Jensen FC; Carlo DJ; Salk J
    Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3348-52. PubMed ID: 2014254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus.
    Montefiori DC; Zhou IY; Barnes B; Lake D; Hersh EM; Masuho Y; Lefkowitz LB
    Virology; 1991 Jun; 182(2):635-43. PubMed ID: 1708933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
    Mascola JR; Lewis MG; Stiegler G; Harris D; VanCott TC; Hayes D; Louder MK; Brown CR; Sapan CV; Frankel SS; Lu Y; Robb ML; Katinger H; Birx DL
    J Virol; 1999 May; 73(5):4009-18. PubMed ID: 10196297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of human immunodeficiency virus-infected lymphocytes with cationized human immunoglobulins.
    Pardridge WM; Buciak J; Yang J; Diagne A
    J Infect Dis; 1994 Sep; 170(3):563-9. PubMed ID: 8077712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of cytotoxic antibody to human immunodeficiency virus-infected cells in humans and its induction in animals after infection or immunization with purified envelope glycoprotein gp120.
    Nara PL; Robey WG; Gonda MA; Carter SG; Fischinger PJ
    Proc Natl Acad Sci U S A; 1987 Jun; 84(11):3797-801. PubMed ID: 3473484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody.
    Tyler DS; Nastala CL; Stanley SD; Matthews TJ; Lyerly HK; Bolognesi DP; Weinhold KJ
    J Immunol; 1989 Feb; 142(4):1177-82. PubMed ID: 2536767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.
    Li A; Katinger H; Posner MR; Cavacini L; Zolla-Pazner S; Gorny MK; Sodroski J; Chou TC; Baba TW; Ruprecht RM
    J Virol; 1998 Apr; 72(4):3235-40. PubMed ID: 9525650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group.
    Lambert JS; Mofenson LM; Fletcher CV; Moye J; Stiehm ER; Meyer WA; Nemo GJ; Mathieson BJ; Hirsch G; Sapan CV; Cummins LM; Jimenez E; O'Neill E; Kovacs A; Stek A
    J Infect Dis; 1997 Feb; 175(2):283-91. PubMed ID: 9203648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.